Advertisement

Applied Health Economics and Health Policy

, Volume 16, Issue 3, pp 303–315 | Cite as

Economic Studies on Non-Communicable Diseases and Injuries in India: A Systematic Review

  • Indrani Gupta
  • Arjun Roy
Systematic Review

Abstract

Background

The burden from non-communicable diseases and injuries (NCDI) in India is increasing rapidly. With low public sector investment in the health sector generally, and a high financial burden on households for treatment, it is important that economic evidence is used to set priorities in the context of NCDI.

Objective

Our objective was to understand the extent to which economic analysis has been used in India to (1) analyze the impact of NCDI and (2) evaluate prevention and treatment interventions. Specifically, this analysis focused on the type of economic analysis used, disease categories, funding patterns, authorship, and author characteristics.

Methods

We conducted a systematic review based on economic keywords to identify studies on NCDI in India published in English between January 2006 and November 2016. In all, 96 studies were included in the review. The analysis used descriptive statistics, including frequencies and percentages.

Results

A majority of the studies were economic impact studies, followed by economic evaluation studies, especially cost-effectiveness analysis. In the costing/partial economic evaluation category, most were cost-description and cost-analysis studies. Under the economic impact/economic burden category, most studies investigated out-of-pocket spending. The studies were mostly on cardiovascular disease, diabetes, and neoplasms. Slightly over half of the studies were funded, with funding coming mainly from outside of India. Half of the studies were led by domestic authors. In most of the studies, the lead author was a clinician or a public health professional; however, most of the economist-led studies were by authors from outside India.

Conclusions

The results indicate the lack of engagement of economists generally and health economists in particular in research on NCDI in India. Demand from health policy makers for evidence-based decision making appears to be lacking, which in turn solidifies the divergence between economics and health policy, and highlights the need to prioritize scarce resources based on evidence regarding what works. Capacity building in health economics needs focus, and the government’s support in this is recommended.

Notes

Acknowledgements

The authors are grateful to Doctors for You for providing a platform to present early results. We acknowledge Nobhojit Roy, Siddarth David, and Kapil Dev Soni for their support and suggestions. We are indebted to Avantika Ranjan for helping us finalize some of the editorial aspects of the manuscript.

Data availability statement

The data that support the findings of this review were generated after examining full-text articles obtained through PubMed. In a few cases, PubMed did not provide full text articles but only a title and an abstract.  In such cases, the articles were located using Sciencedirect, Google Scholar, Karolinska Institute Library (https://kib.ki.se/en), and individual requests to authors. These data are available from the corresponding author, Indrani Gupta, upon reasonable request. Copyright restrictions mean we are unable to provide the full text of any of the articles included in the review.

Author contributions

IG identified research questions, defined exclusion and inclusion criteria, and selected studies based on the criteria. AR searched for and selected studies based on selection criteria, extracted data from the studies, and drew up relevant tables. Both authors analyzed the data and wrote the manuscript.

Compliance with Ethical Standards

Funding

No funding was received for this research.

Conflicts of interest

The authors Indrani Gupta and Arjun Roy have no conflicts of interest to declare.

Supplementary material

40258_2018_370_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 kb)

References

  1. 1.
    World Health Organization. Noncommunicable diseases country profiles 2014. http://apps.who.int/iris/bitstream/10665/128038/1/9789241507509_eng.pdf. Accessed 2 May 2017.
  2. 2.
    World Health Organization. India NCD Country Profile 2014. http://www.who.int/nmh/countries/ind_en.pdf. Accessed 2 May 2017.
  3. 3.
    Reddy KS, et al. Responding to the threat of chronic diseases in India. Lancet. 2005;366(9498):1744–9.CrossRefGoogle Scholar
  4. 4.
    Selvaraj S, Abrol D, Gopakumar K. Access to medicines in India. New Delhi: Academic Foundation; 2014.Google Scholar
  5. 5.
    World Health Organization. General government expenditure on health (GGHE) as % of THE. Global Health Expenditure Database 2012. http://apps.who.int/nha/ database/Select/Indicators/en. Accessed 2 May 2017.
  6. 6.
    Government of India. Ministry of Health and Family Welfare. National Health Accounts Estimates for India, 2014–15. https://mohfw.gov.in/sites/default/files/National%20Health%20Accounts%20Estimates%20Report%202014-15.pdf. Accessed 7 Mar 2018.
  7. 7.
    Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006 (Co-published by Oxford University Press, New York). Available from: https://www.ncbi.nlm.nih.gov/books/NBK11728/.
  8. 8.
    Raftery J, Powell J. Health technology assessment in the UK. Lancet. 2013;382:1278–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Downey LE, Mehndiratta A, Grover A, Gauba V, Sheikh K, Prinja S, Singh R, Cluzeau FA, Dabak S, Teerawattananon Y, Kumar S, Swaminathan S. Institutionalising health technology assessment: establishing the Medical Technology Assessment Board in India. BMJ Glob Health. 2017;2(2):e000259.  https://doi.org/10.1136/bmjgh-2016-000259.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention. Public health economics and tools. 2017. https://www.cdc.gov/stltpublichealth/pheconomics/. Accessed 4 Nov 2017.
  11. 11.
    Vos T, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2013; 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2015;388(10053):1545–602.CrossRefGoogle Scholar
  12. 12.
    Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.Google Scholar
  13. 13.
    Aggarwal K, et al. Comparison of clinical and cost-effectiveness of psoralen + ultraviolet A versus psoralen + sunlight in the treatment of chronic plaque psoriasis in a developing economy. Int J Dermatol. 2013;52(4):478–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Ahmad A, et al. A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital. Indian J Pharmacol. 2015;47(1):90–4.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Ahuja RB, Goswami P. Cost of providing inpatient burn care in a tertiary, teaching, hospital of North India. Burns. 2013;39(4):558–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Alam K, Mahal A. The economic burden of angina on households in South Asia. BMC Public Health. 2014;14:179.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Anchala R, et al. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc. 2015;4(1):e001213.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Basu S, et al. Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ. 2013;347:f6048.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Basu S, Bendavid E, Sood N. Health and economic implications of national treatment coverage for cardiovascular disease in india: cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2015;8(6):541–51.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Basu S, et al. Averting obesity and type 2 diabetes in India through sugar-sweetened beverage taxation: an economic-epidemiologic modeling study. PLoS Med. 2014;11(1):e1001582.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target- versus risk-based blood pressure treatment. Circulation. 2016;133(9):840–8.Google Scholar
  22. 22.
    Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. Int J Pediatr Otorhinolaryngol. 2012;76(2):212–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Buttorff C, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bull World Health Org. 2012;90(11):813–21.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Campbell A, et al. Scalable, sustainable cost-effective surgical care: a model for safety and quality in the developing world, part II: program development and quality care. J Craniofac Surg. 2014;25(5):1680–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Cecchini M, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Chemmanam T, et al. A prospective study on the cost-effective utilization of long-term inpatient video-EEG monitoring in a developing country. J Clin Neurophysiol. 2009;26(2):123–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Chisholm D, et al. Estimating the cost of implementing district mental healthcare plans in five low- and middle-income countries: the PRIME study. Br J Psychiatry. 2016;208(Suppl 56):s71–8.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Daivadanam M, et al. Catastrophic health expenditure and coping strategies associated with acute coronary syndrome in Kerala, India. Indian J Med Res. 2012;136(4):585–92.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Das K, et al. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India. Seizure. 2007;16(7):601–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Das K, et al. Discontinuation of secondary preventive treatment of stroke: an unexplored scenario in India. Clin Neurol Neurosurg. 2010;112(9):766–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Dharmarajan S, et al. Out-of-pocket and catastrophic expenditure on treatment of haemophilia by Indian families. Haemophilia. 2014;20(3):382–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Diaz M, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Donaldson EA, et al. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271–86.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Dorairajan N, et al. Day care surgery in a metropolitan government hospital setting—Indian scenario. Int Surg. 2010;95(1):21–6.PubMedGoogle Scholar
  35. 35.
    Dranitsaris G, Truter I, Lubbe MS. The development of a value based pricing index for new drugs in metastatic colorectal cancer. Eur J Cancer. 2011;47(9):1299–304.PubMedCrossRefGoogle Scholar
  36. 36.
    Dranitsaris G, et al. Improving patient access to cancer drugs in India: using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011;27(1):23–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Engelgau MM, Karan A, Mahal A. The economic impact of non-communicable diseases on households in India. Glob Health. 2012;8:9.CrossRefGoogle Scholar
  38. 38.
    Ghatak N, Trehan A, Bansal D. Financial burden of therapy in families with a child with acute lymphoblastic leukemia: report from north India. Support Care Cancer. 2016;24(1):103–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Goldhaber-Fiebert JD, et al. Inpatient treatment of diabetic patients in Asia: evidence from India, China, Thailand and Malaysia. Diabet Med. 2010;27(1):101–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Goyal S, et al. Risk factors and costs of oral cancer in a tertiary care hospital in Delhi. Asian Pac J Cancer Prev. 2014;15(4):1659–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Gupta S, et al. Challenges of implementing universal newborn hearing screening at a tertiary care centre from India. Indian J Pediatr. 2015;82(8):688–93.PubMedCrossRefGoogle Scholar
  42. 42.
    Gupta V, et al. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2015;18(4):263–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Hackenberg B, et al. Measuring and comparing the cost-effectiveness of surgical care delivery in low-resource settings: cleft lip and palate as a model. J Craniofac Surg. 2015;26(4):1121–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Haripriya A, et al. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at Aravind Eye Hospital. Ophthalmology. 2016;123(2):302–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Home P, et al. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes. J Med Econ. 2015;18(3):230–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Huffman MD, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011;6(6):e20821.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Jansen LA, et al. Improving patient follow-up in developing regions. J Craniofac Surg. 2014;25(5):1640–4.PubMedCrossRefGoogle Scholar
  48. 48.
    John RM, Sung HY, Max W. Economic cost of tobacco use in India, 2004. Tob Control. 2009;18(2):138–43.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Joshi A, et al. Burden of healthcare utilization and out-of-pocket costs among individuals with NCDs in an Indian setting. J Community Health. 2013;38(2):320–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Trop Med Int Health. 2014;19(5):581–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Kesavadev J, et al. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus—a retrospective study. Diabetes Technol Ther. 2012;14(9):772–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Khatib R, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387(10013):61–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis. 2009;13(5):574–9.PubMedGoogle Scholar
  54. 54.
    Kumar A, Gupta NP, Hemal AK. A single institution experience of 141 cases of laparoscopic radical nephrectomy with cost-reductive measures. J Endourol. 2009;23(3):445–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Kumar A, Nagpal J, Bhartia A. Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey. J Assoc Physicians India. 2008;56:667–74.PubMedGoogle Scholar
  56. 56.
    Kumar GA, et al. Burden of out-of-pocket expenditure for road traffic injuries in urban India. BMC Health Serv Res. 2012;12:285.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Kumpatla S, et al. The costs of treating long term diabetic complications in a developing country: a study from India. JAPI. 2013;61:17.Google Scholar
  58. 58.
    Lahiri S, Tempesti T, Gangopadhyay S. Is There an Economic Case for Training Intervention in the Manual Material Handling Sector of Developing Countries? J Occup Environ Med. 2016;58(2):207–14.PubMedCrossRefGoogle Scholar
  59. 59.
    Lamy A, et al. The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. Ann Thorac Surg. 2014;98(5):1620–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Levesque JF, et al. Affording what’s free and paying for choice: comparing the cost of public and private hospitalizations in urban Kerala. Int J Health Plann Manag. 2007;22(2):159–74.CrossRefGoogle Scholar
  61. 61.
    Linde M, Steiner TJ, Chisholm D. Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain. 2015;16:15.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynecol Obstet. 2011;115:S20–5.CrossRefGoogle Scholar
  63. 63.
    Lopes Gde L. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol. 2013;24(Suppl 5):v13–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Mahal A, et al. The economic burden of cancers on Indian households. PLoS One. 2013;8(8):e71853.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Marseille E, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med. 2013;26(8):802–10.PubMedCrossRefGoogle Scholar
  66. 66.
    Megiddo I, et al. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study. Glob Heart. 2014;9(4):391.e3–398.e3.CrossRefGoogle Scholar
  67. 67.
    Megiddo I, et al. Health and economic benefits of public financing of epilepsy treatment in India: an agent-based simulation model. Epilepsia. 2016;57(3):464–74.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Misra UK, et al. Cost of status epilepticus in a tertiary care hospital in India. Seizure. 2015;31:94–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Muranjan M, Vijayalakshmi P. The unforeseen toll of birth defects and their economic burden at a tertiary care public institute in Mumbai. Indian J Pediatr. 2014;81(10):1005–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Nagengast ES, et al. Providing more than health care: the dynamics of humanitarian surgery efforts on the local microeconomy. J Craniofac Surg. 2014;25(5):1622–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Nair KS, et al. Cost of treatment for cancer: experiences of patients in public hospitals in India. Asian Pac J Cancer Prev. 2013;14(9):5049–54.PubMedCrossRefGoogle Scholar
  72. 72.
    Natarajan S, Rudrawar P. Bronchiectasis in western India: clinical presentations and socio-economic burden. J Indian Med Assoc. 2014;112(2):89–92.PubMedGoogle Scholar
  73. 73.
    Okonkwo QL, et al. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008;100(18):1290–300.PubMedCrossRefGoogle Scholar
  74. 74.
    Padhi NR, Padhi P. Use of external fixators for open tibial injuries in the rural third world: panacea of the poor? Injury. 2007;38(2):150–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Pakseresht S, et al. Expenditure audit of women with breast cancer in a tertiary care hospital of Delhi. Indian J Cancer. 2011;48(4):428–37.PubMedCrossRefGoogle Scholar
  76. 76.
    Patankar A, Trivedi P. Monetary burden of health impacts of air pollution in Mumbai, India: implications for public health policy. Public Health. 2011;125(3):157–64.PubMedCrossRefGoogle Scholar
  77. 77.
    Patel RS, et al. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian J Pharmacol. 2014;46(5):485–9.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Patel V, et al. Prioritizing health problems in women in developing countries: comparing the financial burden of reproductive tract infections, anaemia and depressive disorders in a community survey in India. Trop Med Int Health. 2007;12(1):130–9.PubMedGoogle Scholar
  79. 79.
    Pati S, et al. Non communicable disease multimorbidity and associated health care utilization and expenditures in India: cross-sectional study. BMC Health Serv Res. 2014;14:451.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Polack S, et al. Utility values associated with diabetic retinopathy in Chennai, India. Ophthalmic Epidemiol. 2015;22(1):20–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Prajna VN, et al. Economic analysis of corneal ulcers in South India. Cornea. 2007;26(2):119–22.PubMedCrossRefGoogle Scholar
  82. 82.
    Rachapelle S, et al. The cost–utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120(3):566–73.PubMedCrossRefGoogle Scholar
  83. 83.
    Raj M, et al. Micro-economic impact of congenital heart surgery: results of a prospective study from a limited-resource setting. PLoS One. 2015;10(6):e0131348.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Ramachandran A. Socio-economic burden of diabetes in India. J Assoc Physicians India. 2007;55(Suppl):9–12.PubMedGoogle Scholar
  85. 85.
    Ramachandran A, et al. Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care. 2007;30(2):252–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Ramachandran A, et al. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(10):2548–52.PubMedCrossRefGoogle Scholar
  87. 87.
    Ranade AA, et al. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol. 2013;24(Suppl 5):v6–12.PubMedCrossRefGoogle Scholar
  88. 88.
    Rao GN, Bharath S. Cost of dementia care in India: delusion or reality? Indian J Public Health. 2013;57(2):71–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Rao GN, et al. The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State. J Headache Pain. 2015;16:94.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Rao KD, Bhatnagar A, Murphy A. Socio-economic inequalities in the financing of cardiovascular and diabetes inpatient treatment in India. Indian J Med Res. 2011;133:57–63.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Reddy GM, et al. Extent and determinants of cost of road traffic injuries in an Indian city. Indian J Med Sci. 2009;63(12):549–56.PubMedCrossRefGoogle Scholar
  92. 92.
    Reddy GM, Singh A, Singh D. Community based estimation of extent and determinants of cost of injuries in a north Indian city. Indian J Med Sci. 2012;66(1–2):23–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Reddy VK, et al. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol. 2014;46(4):372–7.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Rengasamy S, et al. Comparison of 2 days versus 5 days of octreotide infusion along with endoscopic therapy in preventing early rebleed from esophageal varices: a randomized clinical study. Eur J Gastroenterol Hepatol. 2015;27(4):386–92.PubMedCrossRefGoogle Scholar
  95. 95.
    Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2010;10:13.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Shafie AA, et al. An analysis of the short-and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2014;106(2):319–27.PubMedCrossRefGoogle Scholar
  97. 97.
    Singh A, et al. Risk factors for oral diseases among workers with and without dental insurance in a national social security scheme in India. Int Dent J. 2014;64(2):89–95.PubMedCrossRefGoogle Scholar
  98. 98.
    Somaiya M, et al. Changes in cost of treating schizophrenia: comparison of two studies done a decade apart. Psychiatry Res. 2014;215(3):547–53.PubMedCrossRefGoogle Scholar
  99. 99.
    Soudarssanane M, et al. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J Pediatr. 2007;74(6):567–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Srivastava A, Mohanty SK. Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8(5):e62134.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Subramanian S, et al. Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Org. 2009;87(3):200–6.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Sudhindran S, et al. Cost and efficacy of immunosuppression using generic products following living donor liver transplantation in India. Indian J Gastroenterol. 2012;31(1):20–3.PubMedCrossRefGoogle Scholar
  103. 103.
    Suh GH, et al. International price comparisons of Alzheimer’s drugs: a way to close the affordability gap. Int Psychogeriatr. 2009;21(6):1116–26.PubMedCrossRefGoogle Scholar
  104. 104.
    Sur D, Mukhopadhyay SP. A study on smoking habits among slum dwellers and the impact on health and economics. J Indian Med Assoc. 2007;105(9):492–8.PubMedGoogle Scholar
  105. 105.
    Tharkar S, et al. The socioeconomics of diabetes from a developing country: a population based cost of illness study. Diabetes Res Clin Pract. 2010;89(3):334–40.PubMedCrossRefGoogle Scholar
  106. 106.
    Tharkar S, Satyavani K, Viswanathan V. Cost of medical care among type 2 diabetic patients with a co-morbid condition—Hypertension in India. Diabetes Res Clin Pract. 2009;83(2):263–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Trani JF, et al. Mental illness, poverty and stigma in India: a case-control study. BMJ Open. 2015;5(2):e006355.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Wani MA, et al. Cost analysis of in-patient cancer chemotherapy at a tertiary care hospital. J Cancer Res Ther. 2013;9(3):397–401.PubMedCrossRefGoogle Scholar
  109. 109.
    Gavaza P, et al. The state of health economic research in South Africa. Pharmacoeconomics. 2012;30(10):925–40.PubMedCrossRefGoogle Scholar
  110. 110.
    Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand. Pharmacoeconomics. 2007;25(6):467–79.PubMedCrossRefGoogle Scholar
  111. 111.
    Tran BX, et al. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One. 2014;9(8):e103825.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    UK and India to work together on evidence-informed healthcare policy and practice. 2013. https://www.gov.uk/government/world-location-news/uk-and-india-to-work-together-on-evidence-informed-healthcare-policy-and-practice. Accessed 4 Nov 2017.
  113. 113.
    Prinja S, et al. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy. 2015;13(6):595–613.PubMedCrossRefGoogle Scholar
  114. 114.
    Karan A, Yip W, Mahal A. Extending health insurance to the poor in India: an impact evaluation of Rashtriya Swasthya Bima Yojana on out of pocket spending for healthcare. Soc Sci Med. 2017;181(Supplement C):83–92.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Bloom DE, Cafiero ET, McGovern ME, Prettner K, Stanciole A, Weiss J, Bakkila S, Rosenberg L. The economic impact of non-communicable disease in China and India: estimates, projections, and comparisons. NBER Working Paper No. 19335. http://www.nber.org/papers/w19335.
  116. 116.
    Garg CC, Evans D. What is the impact of non-communicable diseases on national health expenditures: a synthesis of available data. Geneva: World Health Organization; 2011.Google Scholar
  117. 117.
    Gupta I, Kandamuthan S, Upadhyaya D. Economic impact of cardiovascular diseases in India. New Delhi: Institute of Economic Growth University of Delhi; 2006.Google Scholar
  118. 118.
    Mahal AS, Karan A, Engelgau M. Economic implications of non-communicable disease for India. Washington, DC: World Bank; 2010.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Economic GrowthUniversity of Delhi EnclaveDelhiIndia

Personalised recommendations